These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. Solmi M; Veronese N; Thapa N; Facchini S; Stubbs B; Fornaro M; Carvalho AF; Correll CU CNS Spectr; 2017 Oct; 22(5):415-426. PubMed ID: 28181901 [TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. Galling B; Garcia MA; Osuchukwu U; Hagi K; Correll CU Expert Opin Drug Saf; 2015 Aug; 14(8):1181-99. PubMed ID: 26107820 [TBL] [Abstract][Full Text] [Related]
24. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. Zheng W; Cai DB; Yang XH; Li L; Zhang QE; Ng CH; Ungvari GS; Li XB; Ning YP; Xiang YT J Psychiatr Res; 2018 Aug; 103():244-251. PubMed ID: 29906709 [TBL] [Abstract][Full Text] [Related]
25. Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale. Azorin JM; Simon N Expert Opin Drug Metab Toxicol; 2020 Dec; 16(12):1175-1186. PubMed ID: 32930009 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Adjunctive Aripiprazole in Schizophrenia: Meta-Analysis of Randomized Controlled Trials. Zheng W; Zheng YJ; Li XB; Tang YL; Wang CY; Xiang YQ; de Leon J J Clin Psychopharmacol; 2016 Dec; 36(6):628-636. PubMed ID: 27755219 [TBL] [Abstract][Full Text] [Related]
27. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. Kishi T; Sevy S; Chekuri R; Correll CU J Clin Psychiatry; 2013 Jul; 74(7):e642-54. PubMed ID: 23945459 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. Srisurapanont M; Suttajit S; Maneeton N; Maneeton B J Psychiatr Res; 2015 Mar; 62():38-47. PubMed ID: 25619176 [TBL] [Abstract][Full Text] [Related]
29. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. Lao KS; He Y; Wong IC; Besag FM; Chan EW CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371 [TBL] [Abstract][Full Text] [Related]
30. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Zheng W; Li XH; Yang XH; Cai DB; Ungvari GS; Ng CH; Wang SB; Wang YY; Ning YP; Xiang YT Psychol Med; 2018 Jan; 48(1):72-81. PubMed ID: 28528597 [TBL] [Abstract][Full Text] [Related]
31. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Potkin SG; Preda A Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study. Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622 [TBL] [Abstract][Full Text] [Related]
33. Electroconvulsive Therapy Added to Non-Clozapine Antipsychotic Medication for Treatment Resistant Schizophrenia: Meta-Analysis of Randomized Controlled Trials. Zheng W; Cao XL; Ungvari GS; Xiang YQ; Guo T; Liu ZR; Wang YY; Forester BP; Seiner SJ; Xiang YT PLoS One; 2016; 11(6):e0156510. PubMed ID: 27285996 [TBL] [Abstract][Full Text] [Related]
34. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Stip E; Tourjman V Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550 [TBL] [Abstract][Full Text] [Related]
35. Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Zhu XM; Zheng W; Li XH; Cai DB; Yang XH; Ungvari GS; Ng CH; Wang XP; Kulkarni J; Grigg J; Ning YP; Xiang YT Schizophr Res; 2018 Jul; 197():288-293. PubMed ID: 29395611 [TBL] [Abstract][Full Text] [Related]
36. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Swainston Harrison T; Perry CM Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. Correll CU; Rubio JM; Inczedy-Farkas G; Birnbaum ML; Kane JM; Leucht S JAMA Psychiatry; 2017 Jul; 74(7):675-684. PubMed ID: 28514486 [TBL] [Abstract][Full Text] [Related]
38. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. Kishi T; Meltzer HY; Iwata N Int J Neuropsychopharmacol; 2013 Jul; 16(6):1259-66. PubMed ID: 23551924 [TBL] [Abstract][Full Text] [Related]
39. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. Correll CU; Kohegyi E; Zhao C; Baker RA; McQuade R; Salzman PM; Sanchez R; Nyilas M; Carson W J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583 [TBL] [Abstract][Full Text] [Related]
40. Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Zheng W; Li XH; Cai DB; Yang XH; Ungvari GS; Ng CH; Ning YP; Xiang YT Eur Neuropsychopharmacol; 2018 Jan; 28(1):149-158. PubMed ID: 29174529 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]